No Data
Astellas Pharma has signed a Single Option agreement with the French company BIODOL for the pain treatment candidate compound "BDT272."
On the 14th, Astellas Pharma Inc. <4569.T> announced that it has signed an option agreement on the candidate compound "BDT272" for pain treatment created by French BIODOL Therapeutics (Biodol Inc.). Under this agreement, the company has the option rights for the development and sales license in Japan and the Asia Region (excluding China). The company will also pay an option fee to BIODOL Inc. as per the agreement.
Kyorin Signs Option Deal for BIODOL Pain Drug
Kyorin Pharmaceutical Secures Exclusive License for Bayer's Novel OSA Treatment
Express News | Kyorin Pharmaceutical Co Ltd - Kyorin and Bayer Enter Into License Agreement for Novel Obstructive Sleep Apnea (Osa) Treatment:
Volume change rate ranking (10:00) - FISCO, Taiseioton, etc. ranked in.
In the volume change rate ranking, by comparing the average volume of the last 5 days with the volume on the day of distribution, it is possible to understand the trends of market participants' interests, etc. ■ Top volume change rates [As of December 9, 10:32] (Comparison with the average volume of the last 5 days) Stock Code Stock Name Volume 5-Day Average Volume Volume Change Rate Stock Price Change Rate <3807> Fisco 16968500 224898.825 8.43% 0.3709% <1904> Taisei
Kyorin Pharmaceutical: Confirmation letter